ClinicalTrials.gov
Cure8 trial brief
Expanded Access to Upadacitinib
Medications
Upadacitinib
JAK inhibitor
Phase 2 clinical trial
Adult patients
Patients On Biologics
Clinicians
Researchers
Why This Matters
An expanded access program can allow people with Crohn's disease or ulcerative colitis to access upadacitinib before local approval when no other suitable treatments exist.
Who Should Pay Attention
Adults with moderate-to-severe Crohn's disease or ulcerative colitis who lack suitable treatment options, gastroenterologists, and clinical researchers following JAK inhibitor access pathways.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Study statusAvailable
Source depthTrial registry record
What To Know
This listing is an expanded access (compassionate use) program run by the sponsor to provide upadacitinib as an oral solution to people with several immune-mediated conditions, including Crohn's disease and ulcerative colitis. Availability depends on country/territory eligibility and a physician’s assessment that potential benefit outweighs risks.
The record notes participants are excluded if they have other suitable treatment options or qualify for ongoing clinical trials. If you’re interested: talk with your treating gastroenterologist about whether expanded access is available in your region and whether you meet the program’s medical and eligibility criteria.
Expanded access is not the same as participating in a clinical trial and typically has different oversight and data-collection practices.
Keep In Mind
This is a ClinicalTrials.gov expanded access listing (trial-record). Expanded access availability varies by country and requires physician assessment; it is not equivalent to a completed clinical trial or an approved label. The record provides eligibility and exclusion criteria but does not report study results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorAbbVie
Trial IDNCT04159597
Study typeExpanded_access
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 20, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance? - TradingView
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...
DailyMed label update for RINVOQ
A new DailyMed label update for RINVOQ (upadacitinib) outlines FDA-approved uses that include Crohn’s disease and ulcerative colitis and highlights important safety warnings relevant to people with IBD. Patients and...